BACKGROUND: Major depressive disorder (MDD) is common among children and adolescents and is associated with functional impairment and suicide. PURPOSE: To update the 2009 U.S. Preventive Services Task Force (USPSTF) systematic review on screening for and treatment of MDD in children and adolescents in primary care settings. DATA SOURCES: Several electronic searches (May 2007 to February 2015) and searches of reference lists of published literature. STUDY SELECTION: Trials and recent systematic reviews of treatment, test-retest studies of screening, and trials and large cohort studies for harms. DATA EXTRACTION: Data were abstracted by 1 investigator and checked by another; 2 investigators independently assessed study quality. DATA SYNTHESIS: Limited evidence from 5 studies showed that such tools as the Beck Depression Inventory and Patient Health Questionnaire for Adolescents had reasonable accuracy for identifying MDD among adolescents in primary care settings. Six trials evaluated treatment. Several individual fair- and good-quality studies of fluoxetine, combined fluoxetine and cognitive behavioral therapy, escitalopram, and collaborative care demonstrated benefits of treatment among adolescents, with no associated harms. LIMITATION: The review included only English-language studies, narrow inclusion criteria focused only on MDD, high thresholds for quality, potential publication bias, limited data on harms, and sparse evidence on long-term outcomes of screening and treatment among children younger than 12 years. CONCLUSION: No evidence was found of a direct link between screening children and adolescents for MDD in primary care or similar settings and depression or other health-related outcomes. Evidence showed that some screening tools are accurate and some treatments are beneficial among adolescents (but not younger children), with no evidence of associated harms. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
BACKGROUND: Major depressive disorder (MDD) is common among children and adolescents and is associated with functional impairment and suicide. PURPOSE: To update the 2009 U.S. Preventive Services Task Force (USPSTF) systematic review on screening for and treatment of MDD in children and adolescents in primary care settings. DATA SOURCES: Several electronic searches (May 2007 to February 2015) and searches of reference lists of published literature. STUDY SELECTION: Trials and recent systematic reviews of treatment, test-retest studies of screening, and trials and large cohort studies for harms. DATA EXTRACTION: Data were abstracted by 1 investigator and checked by another; 2 investigators independently assessed study quality. DATA SYNTHESIS: Limited evidence from 5 studies showed that such tools as the Beck Depression Inventory and Patient Health Questionnaire for Adolescents had reasonable accuracy for identifying MDD among adolescents in primary care settings. Six trials evaluated treatment. Several individual fair- and good-quality studies of fluoxetine, combined fluoxetine and cognitive behavioral therapy, escitalopram, and collaborative care demonstrated benefits of treatment among adolescents, with no associated harms. LIMITATION: The review included only English-language studies, narrow inclusion criteria focused only on MDD, high thresholds for quality, potential publication bias, limited data on harms, and sparse evidence on long-term outcomes of screening and treatment among children younger than 12 years. CONCLUSION: No evidence was found of a direct link between screening children and adolescents for MDD in primary care or similar settings and depression or other health-related outcomes. Evidence showed that some screening tools are accurate and some treatments are beneficial among adolescents (but not younger children), with no evidence of associated harms. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Authors: Hans Krueger; Sylvia Robinson; Trevor Hancock; Richard Birtwhistle; Jane A Buxton; Bonnie Henry; Jennifer Scarr; John J Spinelli Journal: BMC Health Serv Res Date: 2022-04-26 Impact factor: 2.908
Authors: Michelle Roseman; Nazanin Saadat; Kira E Riehm; Lorie A Kloda; Jill Boruff; Abel Ickowicz; Franziska Baltzer; Laurence Y Katz; Scott B Patten; Cécile Rousseau; Brett D Thombs Journal: Can J Psychiatry Date: 2017-08-29 Impact factor: 4.356
Authors: Hillary Samples; Elizabeth A Stuart; Brendan Saloner; Colleen L Barry; Ramin Mojtabai Journal: J Gen Intern Med Date: 2019-08-06 Impact factor: 5.128
Authors: Michelle Roseman; Lorie A Kloda; Nazanin Saadat; Kira E Riehm; Abel Ickowicz; Franziska Baltzer; Laurence Y Katz; Scott B Patten; Cécile Rousseau; Brett D Thombs Journal: Can J Psychiatry Date: 2016-07-09 Impact factor: 4.356
Authors: Andrew Beck; John C LeBlanc; Kate Morissette; Candyce Hamel; Becky Skidmore; Heather Colquhoun; Eddy Lang; Ainsley Moore; John J Riva; Brett D Thombs; Scott Patten; Heather Bragg; Ian Colman; Gary S Goldfield; Stuart Gordon Nicholls; Kathleen Pajer; Beth K Potter; Robert Meeder; Priya Vasa; Brian Hutton; Beverley J Shea; Eva Graham; Julian Little; David Moher; Adrienne Stevens Journal: Syst Rev Date: 2021-01-12
Authors: Lee Hooper; Asmaa Abdelhamid; Sarah M Ajabnoor; Chizoba Esio-Bassey; Julii Brainard; Tracey J Brown; Diane Bunn; Eve Foster; Charlotte C Hammer; Sarah Hanson; Florence O Jimoh; Hassan Maimouni; Manraj Sandhu; Xia Wang; Lauren Winstanley; Jane L Cross; Ailsa A Welch; Karen Rees; Carl Philpott Journal: Clin Nutr ESPEN Date: 2021-11-19
Authors: Deepa L Sekhar; Krista L Pattison; Alexandra Confair; Alissa Molinari; Eric W Schaefer; James G Waxmonsky; Leslie R Walker-Harding; Perri Rosen; Jennifer L Kraschnewski Journal: JAMA Netw Open Date: 2019-11-01